A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.

[1]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[2]  G. Mufti,et al.  Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  A. Santoro,et al.  Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  B. Falini,et al.  "Designed" grafts for HLA-haploidentical stem cell transplantation. , 2014, Blood.

[5]  L. Xu,et al.  Long-term outcomes of unmanipulated haploidentical HSCT for paediatric patients with acute leukaemia , 2013, Bone Marrow Transplantation.

[6]  Alun Thomas,et al.  Fine mapping of the Bmgr5 quantitative trait locus for allogeneic bone marrow engraftment in mice , 2013, Immunogenetics.

[7]  Yu-Hong Chen,et al.  Long‐term follow‐up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia , 2013, Cancer.

[8]  S. Solomon,et al.  T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Yu-Hong Chen,et al.  Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  A. Nagler,et al.  Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. , 2013, Blood.

[11]  S. Solomon,et al.  Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  M. Konopleva,et al.  Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  M. Martelli,et al.  Haploidentical hematopoietic stem cell transplantation with a megadose T-cell-depleted graft: harnessing natural and adaptive immunity. , 2012, Seminars in oncology.

[14]  W. Hiddemann,et al.  Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. , 2012, The Lancet. Oncology.

[15]  B. Cho,et al.  Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  M. Martelli,et al.  Haploidentical hematopoietic transplantation: current status and future perspectives. , 2011, Blood.

[17]  T. Hyslop,et al.  A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. , 2011, Blood.

[18]  M. Baccarani,et al.  Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. , 2011, Blood.

[19]  S. Yun,et al.  Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. , 2011, Blood.

[20]  Yu-Hong Chen,et al.  The impact of graft composition on clinical outcomes in pediatric patients undergoing unmanipulated HLA‐mismatched/haploidentical hematopoietic stem cell transplantation , 2011, Pediatric blood & cancer.

[21]  B. Falini,et al.  Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. , 2011, Blood.

[22]  J. Plastaras,et al.  TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions , 2011, Bone Marrow Transplantation.

[23]  Allen R. Chen,et al.  HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide , 2010 .

[24]  B. Cho,et al.  Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities , 2010, International journal of hematology.

[25]  I. Kerridge,et al.  Pre‐transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[26]  V. Hasselblad,et al.  Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  M. Aljurf,et al.  High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection. , 2010, Hematology/oncology and stem cell therapy.

[28]  K. Ishiyama,et al.  Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center , 2010, International journal of hematology.

[29]  K. van Besien,et al.  The next frontier for stem cell transplantation: finding a donor for all. , 2010, JAMA.

[30]  C. Huff,et al.  Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  E. Shpall,et al.  Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT , 2010, Bone Marrow Transplantation.

[32]  E. Ball,et al.  Optimal use of G-CSF administration after hematopoietic SCT , 2009, Bone Marrow Transplantation.

[33]  B. Sandmaier,et al.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  Yu-Hong Chen,et al.  Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  Arnon Nagler,et al.  A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. , 2008, Blood.

[36]  Allen R. Chen,et al.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  B. Sandmaier,et al.  Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[38]  M. Horowitz,et al.  Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. , 2006, Blood.

[39]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  W. Berdel,et al.  Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. , 2005, Blood.

[41]  C. Mecucci,et al.  Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Yoo-Jin Kim,et al.  The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2005, Blood.

[43]  Y. Kim,et al.  Haplotype mismatched transplantation using high doses of peripheral blood CD34+ cells together with stratified conditioning regimens for high-risk adult acute myeloid leukemia patients: a pilot study in a single Korean institution , 2005, Bone Marrow Transplantation.

[44]  K. Matsuo,et al.  Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. , 2004, Blood.

[45]  A. Bacigalupo.  Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus , 2004, Bone Marrow Transplantation.

[46]  M. Labopin,et al.  Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  S. Singhal,et al.  Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients , 2004, Bone Marrow Transplantation.

[48]  R. Bociek,et al.  Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study. , 2003, Cytotherapy.

[49]  H. Vriesendorp.  Aims of conditioning. , 2003, Experimental hematology.

[50]  V. Vitale,et al.  Low-dose fractionated total body irradiation (TBI) adversely affects prognosis of patients with leukemia receiving an HLA-matched allogeneic bone marrow transplant from an unrelated donor (UD-BMT) , 2002, Bone Marrow Transplantation.

[51]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[52]  A. Tosti,et al.  Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. , 2001, Blood.

[53]  J. Tiercy,et al.  Bone marrow transplantation with unrelated donors: what is the probability of identifying an HLA-A/B/Cw/DRB1/B3/B5/DQB1-matched donor? , 2000, Bone Marrow Transplantation.

[54]  T. Hartung,et al.  Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions , 1999, Clinical pharmacology and therapeutics.

[55]  R. Champlin,et al.  Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. , 1999, Oncology.

[56]  W. Vaughan.  Reinventing Bone Marrow Transplantation , 1999 .

[57]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[58]  M. Mielcarek,et al.  Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. , 1998, Blood.

[59]  S. Strober,et al.  Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. , 1997, Blood.

[60]  J. Hansen,et al.  Hematopoietic stem cell transplants from unrelated donors , 1997, Immunological reviews.

[61]  J P Klein,et al.  Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  E. Romond,et al.  Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. , 1996, Transplantation.

[63]  J. Ferrara,et al.  Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.

[64]  M. Martelli,et al.  Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. , 1995, Immunology today.

[65]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[66]  F. Aversa,et al.  Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. , 1994, Blood.

[67]  F. Appelbaum,et al.  Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. , 1990, Blood.

[68]  T. Lapidot,et al.  Induction of donor-type chimerism in murine recipients of bone marrow allografts by different radiation regimens currently used in treatment of leukemia patients. , 1990, Blood.

[69]  K. Sullivan,et al.  Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. , 1989, The New England journal of medicine.

[70]  B. Dupont,et al.  Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. , 1986, Blood.

[71]  R. Storb,et al.  Marrow transplantation from related donors other than HLA-identical siblings. , 1985, The New England journal of medicine.

[72]  D. Hedley,et al.  MISMATCHED FAMILY DONORS FOR BONE-MARROW TRANSPLANTATION AS TREATMENT FOR ACUTE LEUKAEMIA , 1983, The Lancet.

[73]  G. Shenfield,et al.  GUAR AND DIABETES , 1979, The Lancet.

[74]  D. Carlson,et al.  TRANSPLANTATION OF ALLOGENEIC AND XENOGENEIC (RAT) MARROW IN IRRADIATED MICE AS AFFECTED BY RADIATION EXPOSURE RATES , 1969, Transplantation.

[75]  T. Lamparelli,et al.  Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[76]  L. Kanz,et al.  Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts , 2011, Leukemia.

[77]  B. Cho,et al.  The Outcome of Unrelated Hematopoietic Stem Cell Transplants with Total Body Irradiation (800 cGy) and Cyclophosphamide (120 mg/kg) in Adult Patients with Acquired Severe Aplastic Anemia. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[78]  Yoo-Jin Kim,et al.  Risk-Adapted Preemptive Therapy for Cytomegalovirus Disease after Allogeneic Stem Cell Transplantation: A Single-Center Experience in Korea , 2005, International journal of hematology.